For 2QFY2017, Cadila Healthcare posted lower than expected results with sales
at Rs2,336cr (vs. Rs2,737cr expected vs. Rs2,267cr in 2QFY2016), a yoy growth of
3.1%. On the operating front, the EBITDA margin came in at 21.4% (vs. 21.7%
expected vs. 20.3% in 2QFY2016). The dip in the OPM was saved in spite of an
underperformance on the sales front as the GPM improved to 63.9% (vs. 64.8%
in 2QFY2016). The Adj. net profit came in at Rs338cr (vs. Rs461cr expected vs.
Rs475cr in 2QFY2016), a yoy de-growth of 29.0%. We maintain our Neutral
rating on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...